Counterpoint: Establishing consensus in the diagnosis of GDM following the HAPO study

H. David McIntyre; Boyd E. Metzger; Donald R. Coustan; Alan R. Dyer; David R. Hadden; Moshe Hod; Lynn P. Lowe; Jeremy J.N. Oats; Bengt Persson

doi:10.1007/s11892-014-0497-x

Counterpoint: Establishing consensus in the diagnosis of GDM following the HAPO study

H. David McIntyre, Boyd E. Metzger^*, Donald R. Coustan, Alan R. Dyer, David R. Hadden, Moshe Hod, Lynn P. Lowe, Jeremy J.N. Oats, Bengt Persson

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

34 Scopus citations

Abstract

The International Association of Diabetes in Pregnancy Study Groups (IADPSG) recommended a new protocol of 1-step testing with a 75 g oral glucose tolerance test for gestational diabetes in 2010. Since that time, these recommendations have been carefully scrutinized and accepted by a variety of organizations, but challenged or rejected by others. In the current review, we present more details regarding the background to the development of the IADPSG recommendations and seek to place them in context with the available epidemiologic and randomized controlled trial data. In this "counterpoint, " we also provide specific rebuttal for errors of fact and disputed contentions provided by Long and Cundy in their 2013 article in Current Diabetes Reports.

Original language	English (US)
Article number	497
Journal	Current diabetes reports
Volume	14
Issue number	6
DOIs	https://doi.org/10.1007/s11892-014-0497-x
State	Published - Jun 2014

Funding

Acknowledgment Donald R. Coustan has received grant support from NICHD. Compliance with Ethics Guidelines Conflict of Interest H. David McIntyre has board membership with the Mater Research Institute. He has received speakers’ fees from Novo Nordisk, Eli Lilly, Sanofi-Aventis, and AstraZeneca. He has received travel/accommodations expenses covered or reimbursed for travel to meetings from Novo Nordisk, Sanofi-Aventis, and AstraZeneca. Donald R. Coustan has received royalties for textbooks written or edited. He has received honoraria from various academic institutions and professional organizations for lectures given, none from commercial entities. He has received travel expense reimbursement and coverage for giving lectures at various academic institutions and professional organizations, none from commercial entities. He was regional director for North America in the HAPO study. Boyd E. Metzger, Alan R. Dyer, David R. Hadden, Moshe Hod, Lynn P. Lowe, Jeremy J.N, Oats, and Bengt Persson declare that they have no conflict of interest.

Keywords

Gestational diabetes mellitus (GDM)
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11892-014-0497-x

Cite this

@article{6febf78191e5486199900b7293571928,

title = "Counterpoint: Establishing consensus in the diagnosis of GDM following the HAPO study",

abstract = "The International Association of Diabetes in Pregnancy Study Groups (IADPSG) recommended a new protocol of 1-step testing with a 75 g oral glucose tolerance test for gestational diabetes in 2010. Since that time, these recommendations have been carefully scrutinized and accepted by a variety of organizations, but challenged or rejected by others. In the current review, we present more details regarding the background to the development of the IADPSG recommendations and seek to place them in context with the available epidemiologic and randomized controlled trial data. In this {"}counterpoint, {"} we also provide specific rebuttal for errors of fact and disputed contentions provided by Long and Cundy in their 2013 article in Current Diabetes Reports.",

keywords = "Gestational diabetes mellitus (GDM), Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study",

author = "McIntyre, {H. David} and Metzger, {Boyd E.} and Coustan, {Donald R.} and Dyer, {Alan R.} and Hadden, {David R.} and Moshe Hod and Lowe, {Lynn P.} and Oats, {Jeremy J.N.} and Bengt Persson",

note = "Funding Information: Acknowledgment Donald R. Coustan has received grant support from NICHD. Compliance with Ethics Guidelines Conflict of Interest H. David McIntyre has board membership with the Mater Research Institute. He has received speakers{\textquoteright} fees from Novo Nordisk, Eli Lilly, Sanofi-Aventis, and AstraZeneca. He has received travel/accommodations expenses covered or reimbursed for travel to meetings from Novo Nordisk, Sanofi-Aventis, and AstraZeneca. Donald R. Coustan has received royalties for textbooks written or edited. He has received honoraria from various academic institutions and professional organizations for lectures given, none from commercial entities. He has received travel expense reimbursement and coverage for giving lectures at various academic institutions and professional organizations, none from commercial entities. He was regional director for North America in the HAPO study. Boyd E. Metzger, Alan R. Dyer, David R. Hadden, Moshe Hod, Lynn P. Lowe, Jeremy J.N, Oats, and Bengt Persson declare that they have no conflict of interest.",

year = "2014",

month = jun,

doi = "10.1007/s11892-014-0497-x",

language = "English (US)",

volume = "14",

journal = "Current diabetes reports",

issn = "1534-4827",

publisher = "Current Medicine Group",

number = "6",

}

TY - JOUR

T1 - Counterpoint

T2 - Establishing consensus in the diagnosis of GDM following the HAPO study

AU - McIntyre, H. David

AU - Metzger, Boyd E.

AU - Coustan, Donald R.

AU - Dyer, Alan R.

AU - Hadden, David R.

AU - Hod, Moshe

AU - Lowe, Lynn P.

AU - Oats, Jeremy J.N.

AU - Persson, Bengt

N1 - Funding Information: Acknowledgment Donald R. Coustan has received grant support from NICHD. Compliance with Ethics Guidelines Conflict of Interest H. David McIntyre has board membership with the Mater Research Institute. He has received speakers’ fees from Novo Nordisk, Eli Lilly, Sanofi-Aventis, and AstraZeneca. He has received travel/accommodations expenses covered or reimbursed for travel to meetings from Novo Nordisk, Sanofi-Aventis, and AstraZeneca. Donald R. Coustan has received royalties for textbooks written or edited. He has received honoraria from various academic institutions and professional organizations for lectures given, none from commercial entities. He has received travel expense reimbursement and coverage for giving lectures at various academic institutions and professional organizations, none from commercial entities. He was regional director for North America in the HAPO study. Boyd E. Metzger, Alan R. Dyer, David R. Hadden, Moshe Hod, Lynn P. Lowe, Jeremy J.N, Oats, and Bengt Persson declare that they have no conflict of interest.

PY - 2014/6

Y1 - 2014/6

N2 - The International Association of Diabetes in Pregnancy Study Groups (IADPSG) recommended a new protocol of 1-step testing with a 75 g oral glucose tolerance test for gestational diabetes in 2010. Since that time, these recommendations have been carefully scrutinized and accepted by a variety of organizations, but challenged or rejected by others. In the current review, we present more details regarding the background to the development of the IADPSG recommendations and seek to place them in context with the available epidemiologic and randomized controlled trial data. In this "counterpoint, " we also provide specific rebuttal for errors of fact and disputed contentions provided by Long and Cundy in their 2013 article in Current Diabetes Reports.

AB - The International Association of Diabetes in Pregnancy Study Groups (IADPSG) recommended a new protocol of 1-step testing with a 75 g oral glucose tolerance test for gestational diabetes in 2010. Since that time, these recommendations have been carefully scrutinized and accepted by a variety of organizations, but challenged or rejected by others. In the current review, we present more details regarding the background to the development of the IADPSG recommendations and seek to place them in context with the available epidemiologic and randomized controlled trial data. In this "counterpoint, " we also provide specific rebuttal for errors of fact and disputed contentions provided by Long and Cundy in their 2013 article in Current Diabetes Reports.

KW - Gestational diabetes mellitus (GDM)

KW - Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study

UR - http://www.scopus.com/inward/record.url?scp=84901738606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901738606&partnerID=8YFLogxK

U2 - 10.1007/s11892-014-0497-x

DO - 10.1007/s11892-014-0497-x

M3 - Review article

C2 - 24777652

AN - SCOPUS:84901738606

SN - 1534-4827

VL - 14

JO - Current diabetes reports

JF - Current diabetes reports

IS - 6

M1 - 497

ER -

Counterpoint: Establishing consensus in the diagnosis of GDM following the HAPO study

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this